Implantable TANTALUS Device Results Presented at London Diabetes Tech Conference

Written by Matt Nilsen

The TANTALUS active implantable pulse generator device helped maintain healthier blood glucose levels for 2 years in moderately obese type 2 diabetic study participants. These findings, stemming from clinical studies, were presented in London at the Advanced Technologies & Treatments for Diabetes conference in February 2011.

In his presentation, Professor Dirk Müller-Wieland from Asklepios Clinic St. Georg in Hamburg, Germany, shared evidence that the TANTALUS device significantly reduced HbA1c in diabetic treatment recipients. TANTALUS users also experienced notably reduced blood pressure, improved lipid profiles, and reductions in their body mass indices.

According to another presenter, Professor Bernhard Ludvik from the Medical University of Vienna, “TANTALUS is well tolerated by patients and maintains its beneficial effect on blood glucose levels and weight for periods of at least 2 years."

The most recent results were a graduation from outcomes presented in 2009, showing that moderately obese implantees in a 6-month trial achieved a 1% HbA1c reduction by the end of the study.1 The current results suggest that patients using the TANTALUS device can maintain that benefit for at least 2 years.

The TANTALUS system is currently approved for marketing in the European Union. The company has not yet indicated its intentions to seek approval for the device in the United States. However, TANTALUS’s manufacturer, MetaCure, Inc., is currently sponsoring clinical studies to further evaluate the implantable device’s potential in moderately obese people with diabetes. The largest study, just initiated, seeks to enroll 400 moderately obese diabetic patients in European trial sites.2

TANTALUS is intended for moderately obese people with diabetes who do not meet the guidelines for gastric bypass surgery. It is not likely to compete against gastric bypass surgery’s ability to help severely obese patients shed dozens of pounds and dramatically lower body mass index and blood glucose. However, it may offer a significant weapon for moderately obese diabetics.



  1. Sanmiguel C, Conklin J, Cunneen S, et al, Gastric electrical stimulation with the TANTALUS System in obese type 2 diabetes patients: effect on weight and glycemic control. J Diabetes Sci Technol. 2009 Jul 1;3(4):964-70. PMID: 20144347
  2. Clinical TANTALUS Therapy in Type 2 Diabetic Patients Intolerant or Inadequately Responsive to GLP-1 Receptor Agonist Therapy. Upadated February 23, 2011. Accessed February 25, 2011.


Continue Reading

Electronic Health Records and Computerized Physician Order Entry Linked to Physician Burnout and Professional Dissatisfaction